Pharmacokinetic (PK) and pharmacodynamic (PD) studies are essential for developing new medicines and ensuring early access to treatments for special populations such as pregnant women and children. These studies are crucial for preliminary safety assessments, determining appropriate dosing, and evaluating drug-drug interactions.
This summer, join our online course to gain a comprehensive understanding of how to design PK/PD studies, analyze pharmacology data, and interpret results effectively. Organized by the Radboudumc Department of Pharmacy, Pharmacology and Toxicology, and the Radboud Center for Infectious Diseases, this course provides practical, expert-led training in clinical pharmacology.
The role of clinical pharmacology is well-established in both research and practice, with its main goal being to establish doses that are both safe and effective. By participating in this course, you’ll develop the skills needed to describe and predict PK/PD behavior and apply these techniques in your work.
Course details
- 3 weekly online modules (~13 hours per module)
- Topics include:
- General concepts of pharmacokinetics.
- Pharmacokinetic analyses.
- Understanding PK/PD modeling and simulation.
- Introduction to bioanalytical methods.
- Includes an online exam to test your knowledge.
Learning objectives
- Demonstrate a comprehensive knowledge of all fields relevant to pharmacokinetic research, understand the role of bioanalytics in PK research, and interpret and critically evaluate PK studies.
- Describe the differences between bottom-up and top-down approaches in PK modelling, perform a physiologically-based PK modelling simulation, understand to what extent pharmacokinetics parameters can predict the pharmacodynamic properties of a drug.
- Design a non-compartmental PK study, understand how to calculate bioequivalence, and how to derive relevant pharmacokinetic parameters answering your research question.
- Comprehend clinical implementation of pharmacokinetics and how this can contribute to drug dosing in various populations and assessment of drug-drug interactions.
